Viewing Study NCT01515527

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 5:06 AM
Ignite Modification Date: 2026-02-07 @ 10:52 AM
Study NCT ID: NCT01515527
Status: RECRUITING
Last Update Posted: 2025-08-07
First Post: 2012-01-13
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
Sponsor: M.D. Anderson Cancer Center
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Leukemia View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Leukemia View
None Acute myeloid leukemia View
None AML View
None myelodysplastic syndrome View
None MDS View
None Cytarabine View
None Ara-C View
None Cytosar View
None DepoCyt View
None Cytosine Arabinosine Hydrochloride View
None Decitabine View
None Dacogen View
None Cladribine View
None Leustatin View
None 2-CdA View